# A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

> **NCT02124668** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 30 (actual)

## Conditions studied

- Castration-Resistant Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02124668
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-23
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124668, "A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02124668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*